Myelodysplastic Syndrome Pipeline Market Report 2021: Comprehensive Insights for 120+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Myelodysplastic syndrome - Pipeline Insight, 2021," report provides comprehensive insights for 120+ companies and 120+ pipeline drugs in Myelodysplastic syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Myelodysplastic syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Myelodysplastic syndrome.
Myelodysplastic syndrome Emerging Drugs Chapters
This segment of the Myelodysplastic syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myelodysplastic syndrome Emerging Drugs
Tamibarotene: Syros Pharmaceuticals
Tamibarotene (formerly SY-1425) is an oral first-in-class selective retinoic acid receptor alpha (RAR?) agonist that we are developing for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. The company is currently investigating tamibarotene in the SELECT-MDS-1 (Phase 3) trial in RARA-positive patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
Sabatolimab: Novarits Oncology
Sabatolimab binds to TIM-3 on the surface of T-cells, releasing the brakes that the tumour applied to the immune system. This allows it to function normally against cancer cells, reducing tumor growth.
CX-01: Cantex Pharmaceuticals
CX-01 is a new chemical entity derived from unfractionated heparin with very low anticoagulant activity. CX-01 targets key protein pathways important for AML blast cell migration to the bone marrow and retention of these cells in the marrow where they are protected from chemotherapy. CX-01 also binds with proteins involved in chemotherapy resistance and the delay in platelet recovery after chemotherapy. Together, these activities are understood to sensitize AML blasts to chemotherapy and improve clinical responses. These mechanisms of action support the potential for development in myelodysplastic syndrome, multiple myeloma, and lymphomas.
AMV564: Amphivena Therapeutics
AMV564 harnesses the patient's own T-cells to both relieve immune suppression and restore anti-cancer T cell function systemically and in the tumor microenvironment. AMV564 induces T cell mediated killing of myeloid derived suppressor cells (MDSC) and AML leukemic blasts, while sparing differentiated myeloid cells (e.g., neutrophils and monocytes) and drives activation and repolarization of T cells and improved T effector function.
Myelodysplastic syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Myelodysplastic syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Myelodysplastic syndrome
There are approx. 120+ key companies which are developing the therapies for Myelodysplastic syndrome. The companies which have their Myelodysplastic syndrome drug candidates in the most advanced stage, i.e. phase III include, Syros Pharmaceuticals.
Myelodysplastic syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myelodysplastic syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myelodysplastic syndrome drugs.
Key Questions Answered
- How many companies are developing Myelodysplastic syndrome drugs?
- How many Myelodysplastic syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myelodysplastic syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myelodysplastic syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myelodysplastic syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Syros Pharmaceuticals
- Novarits Oncology
- Cantex Pharmaceuticals
- Amphivena Therapeutics
- Bristol Myers Squibb
- Sumitomo Dainippon Pharma
- Antengene Corporation
- Geron Corporation
- Lixte Biotechnology Holdings, Inc.
- Opsona Therapeutics
- ALX Oncology
- MedImmune LLC
- MEI Pharma
- Gilead Sciences
- H3 Biomedicine Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Syntrix Biosystems, Inc.
- Onconova Therapeutics
- BioMed Valley Discoveries, Inc
- Incyte Corporation
- I-Mab Biopharma Co. Ltd.
- Keros Therapeutics
- Aprea Therapeutics
- BioLite, Inc.
- Jazz Pharmaceuticals
- Ryvu Therapeutics SA
- Sunesis Pharmaceuticals
- Celyad Oncology SA
- Innovent Biologics (Suzhou) Co. Ltd.
- ON 01910.Na
- BLEX 404
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/20by08
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900